Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. 1996

R C Coombes, and J M Bliss, and J Wils, and F Morvan, and M Espié, and D Amadori, and P Gambrosier, and M Richards, and M Aapro, and A Villar-Grimalt, and C McArdle, and F R Pérez-López, and P Vassilopoulos, and E P Ferreira, and C E Chilvers, and G Coombes, and E M Woods, and M Marty
Medical Oncology Unit, Charing Cross Hospital, United Kingdom.

OBJECTIVE To determine whether a combination chemotherapy regimen that contains epirubicin (fluorouracil, epirubicin, and cyclophosphamide [FEC]) is superior to the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in premenopausal women with axillary node-positive operable breast cancer. METHODS The International Collaborative Cancer Group (ICCG) conducted a large randomized trial in which two alternative schedules were used according to participating center: CMF1 versus FEC1 and CMF2 versus FEC2. RESULTS Seven hundred fifty-nine patients were entered onto the trial. At a median follow-up time of 4.5 years, no significant benefit for the anthracycline-containing regimen was observed in terms of relapse-free (P = .61) or overall survival (P = .13). FEC1 and CMF1 appear to be of similar efficacy, but there is a suggestion that FEC2 may be superior to CMF2, since patients who received FEC2 had improved overall (P = .02) and relapse-free survival (P = .03) rates. Nausea and vomiting and alopecia were more common in the epirubicin-containing regimen (P = .001). CONCLUSIONS We conclude that the FEC2 regimen, in which epirubicin replaced the methotrexate in CMF, is the preferable adjuvant chemotherapy regimen for premenopausal patients with operable axillary node-positive breast cancer.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008408 Mastectomy Surgical procedure to remove one or both breasts. Mammectomy,Mammectomies,Mastectomies
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D012044 Regression Analysis Procedures for finding the mathematical function which best describes the relationship between a dependent variable and one or more independent variables. In linear regression (see LINEAR MODELS) the relationship is constrained to be a straight line and LEAST-SQUARES ANALYSIS is used to determine the best fit. In logistic regression (see LOGISTIC MODELS) the dependent variable is qualitative rather than continuously variable and LIKELIHOOD FUNCTIONS are used to find the best relationship. In multiple regression, the dependent variable is considered to depend on more than a single independent variable. Regression Diagnostics,Statistical Regression,Analysis, Regression,Analyses, Regression,Diagnostics, Regression,Regression Analyses,Regression, Statistical,Regressions, Statistical,Statistical Regressions
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

R C Coombes, and J M Bliss, and J Wils, and F Morvan, and M Espié, and D Amadori, and P Gambrosier, and M Richards, and M Aapro, and A Villar-Grimalt, and C McArdle, and F R Pérez-López, and P Vassilopoulos, and E P Ferreira, and C E Chilvers, and G Coombes, and E M Woods, and M Marty
December 2000, Cancer,
R C Coombes, and J M Bliss, and J Wils, and F Morvan, and M Espié, and D Amadori, and P Gambrosier, and M Richards, and M Aapro, and A Villar-Grimalt, and C McArdle, and F R Pérez-López, and P Vassilopoulos, and E P Ferreira, and C E Chilvers, and G Coombes, and E M Woods, and M Marty
January 2005, PharmacoEconomics,
R C Coombes, and J M Bliss, and J Wils, and F Morvan, and M Espié, and D Amadori, and P Gambrosier, and M Richards, and M Aapro, and A Villar-Grimalt, and C McArdle, and F R Pérez-López, and P Vassilopoulos, and E P Ferreira, and C E Chilvers, and G Coombes, and E M Woods, and M Marty
August 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R C Coombes, and J M Bliss, and J Wils, and F Morvan, and M Espié, and D Amadori, and P Gambrosier, and M Richards, and M Aapro, and A Villar-Grimalt, and C McArdle, and F R Pérez-López, and P Vassilopoulos, and E P Ferreira, and C E Chilvers, and G Coombes, and E M Woods, and M Marty
July 2010, Breast cancer (Tokyo, Japan),
R C Coombes, and J M Bliss, and J Wils, and F Morvan, and M Espié, and D Amadori, and P Gambrosier, and M Richards, and M Aapro, and A Villar-Grimalt, and C McArdle, and F R Pérez-López, and P Vassilopoulos, and E P Ferreira, and C E Chilvers, and G Coombes, and E M Woods, and M Marty
August 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R C Coombes, and J M Bliss, and J Wils, and F Morvan, and M Espié, and D Amadori, and P Gambrosier, and M Richards, and M Aapro, and A Villar-Grimalt, and C McArdle, and F R Pérez-López, and P Vassilopoulos, and E P Ferreira, and C E Chilvers, and G Coombes, and E M Woods, and M Marty
July 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R C Coombes, and J M Bliss, and J Wils, and F Morvan, and M Espié, and D Amadori, and P Gambrosier, and M Richards, and M Aapro, and A Villar-Grimalt, and C McArdle, and F R Pérez-López, and P Vassilopoulos, and E P Ferreira, and C E Chilvers, and G Coombes, and E M Woods, and M Marty
December 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R C Coombes, and J M Bliss, and J Wils, and F Morvan, and M Espié, and D Amadori, and P Gambrosier, and M Richards, and M Aapro, and A Villar-Grimalt, and C McArdle, and F R Pérez-López, and P Vassilopoulos, and E P Ferreira, and C E Chilvers, and G Coombes, and E M Woods, and M Marty
October 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R C Coombes, and J M Bliss, and J Wils, and F Morvan, and M Espié, and D Amadori, and P Gambrosier, and M Richards, and M Aapro, and A Villar-Grimalt, and C McArdle, and F R Pérez-López, and P Vassilopoulos, and E P Ferreira, and C E Chilvers, and G Coombes, and E M Woods, and M Marty
January 2010, Breast cancer research and treatment,
R C Coombes, and J M Bliss, and J Wils, and F Morvan, and M Espié, and D Amadori, and P Gambrosier, and M Richards, and M Aapro, and A Villar-Grimalt, and C McArdle, and F R Pérez-López, and P Vassilopoulos, and E P Ferreira, and C E Chilvers, and G Coombes, and E M Woods, and M Marty
January 1996, European journal of clinical pharmacology,
Copied contents to your clipboard!